相关实验视频

Updated: Jan 8, 2026

Sustained Administration of β-cell Mitogens to Intact Mouse Islets Ex Vivo Using Biodegradable Poly(lactic-co-glycolic acid) Microspheres

Sustained Administration of β-cell Mitogens to Intact Mouse Islets Ex Vivo Using Biodegradable Poly(lactic-co-glycolic acid) Microspheres

Published on: November 5, 2016

在糖尿病小鼠中,分泌GLP-1的工程MSC增强β细胞存活率并改善血糖控制

Zheng Huang¹, Yuyi Zhang¹, Jingwen Tian¹

¹Guangxi Key Laboratory of Special Biomedicine, School of Medicine, Guangxi University, Nanning, 530004, China.

Biochemical and biophysical research communications

|December 11, 2025

概括

释放GLP-1的工程干细胞显示出1型糖尿病 (T1D) 治疗的前景. 这些修改后的细胞在小鼠模型中改善了葡萄糖控制和小岛健康,提供了潜在的新疗法.

科学领域:

免疫学免疫学免疫学
内分泌学在内分泌学.
再生医学是一种再生医学.

背景情况:

1型糖尿病 (T1D) 是由胰腺β细胞的自身免疫破坏引起的,需要胰岛素治疗或移植.
目前针对T1D的治疗方法面临着诸如供体稀缺和长期管理挑战等局限性.
人类带衍生中干细胞 (hUC-MSCs) 显示出免疫调节和组织修复能力,表明治疗潜力.

研究的目的:

为了设计hUC-MSCs以使用非病毒电穿孔稳定分泌葡萄糖类-1 (GLP-1).
在T1D的临床前模型中评估GLP-1分泌hUC-MSCs的治疗疗效.

主要方法:

通过电穿孔修改hUC-MSCs以表达和分泌GLP-1.
使用qPCR和ELISA证实了GLP-1的表达和分泌.
GLP-1-MSC对β细胞功能和存活率的影响在体外进行了评估.
评估了GLP-1-MSCs在链杆菌素诱导的T1D小鼠模型中的疗效.

主要成果:

设计的GLP-1-MSCs成功地表达和分泌GLP-1.
来自GLP-1-MSCs的条件介质增强了β细胞存活率和对葡萄糖敏感的胰岛素分泌.
在T1D小鼠中,GLP-1-MSCs的全身用药显著降低了高血糖.
GLP-1-MSC治疗改善了葡萄糖耐受性,胰岛素耐受性,并保留了胰腺小岛结构.

结论:

非病毒电穿孔是一种有效的方法来产生治疗性GLP-1分泌hUC-MSCs.
GLP-1-MSCs显示出作为T1D的基于细胞的治疗方法的巨大潜力.
这些工程细胞为T1D治疗的未来临床应用提供了一个有前途,安全和高效的战略.

关键词:

电穿孔是一种电子穿孔.这就是GLP-1.介质细胞干细胞介质细胞干细胞非病毒基因传递非病毒基因传递 1 型糖尿病 1 型糖尿病

更多相关视频

Scaffold-supported Transplantation of Islets in the Epididymal Fat Pad of Diabetic Mice

Scaffold-supported Transplantation of Islets in the Epididymal Fat Pad of Diabetic Mice

Published on: July 23, 2017

Leprdb Mouse Model of Type 2 Diabetes: Pancreatic Islet Isolation and Live-cell 2-Photon Imaging Of Intact Islets

Leprdb Mouse Model of Type 2 Diabetes: Pancreatic Islet Isolation and Live-cell 2-Photon Imaging Of Intact Islets

Published on: May 11, 2015

相关概念视频

Glucagon-like Receptor Agonists

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...